Mounjaro® (tirzepatide) is a prescription injectable medication developed by Eli Lilly, designed to enhance blood sugar control in adults with type 2 diabetes when used alongside diet and exercise. It also has substantial weight loss advantages, leading to its approval under the Zepbound™ brand for chronic weight management. The active compound, tirzepatide, acts as a dual GIP and GLP-1 receptor agonist that aids in blood sugar regulation and promotes weight reduction. Mounjaro is offered in pre-filled KwikPen® injectors with different strengths, such as 2.5 mg/0.5 mL and 5 mg/0.5 mL, among others. Each pen provides a once-weekly dose administered subcutaneously. It's not appropriate for individuals with type 1 diabetes or those with a history of pancreatitis. Common side effects may include nausea, vomiting, diarrhea, a decrease in appetite, and constipation. Animal studies have linked it to thyroid C-cell tumors, but it's unclear if this risk extends to humans. Mounjaro should be used under healthcare professional guidance to ensure its safe and effective use.